A nitrogen molecular entity resulting from the formal substitution of one or more of the hydrogens of triazene.
ChEBI ID: 72573
Member | Definition | Role |
---|---|---|
5-(3-methyl-1-triazeno)imidazole-4-carboxamide | A monocarboxylic acid amide that is dacarbazine in which one of the methyl groups is replaced by a hydrogen. It is the active metabolite of dacarbazine, and is also produced by spontaneous hydrolysis of temozolomide in the body. | MTIC |
dacarbazine | A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. | dacarbazine |
diminazene | A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group. | diminazene |
temozolomide | An imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma. | temozolomide |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 219 (3.33) | 18.7374 |
1990's | 290 (4.40) | 18.2507 |
2000's | 1,239 (18.81) | 29.6817 |
2010's | 3,354 (50.93) | 24.3611 |
2020's | 1,484 (22.53) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 855 (12.53%) | 5.53% |
Reviews | 645 (9.45%) | 6.00% |
Case Studies | 553 (8.11%) | 4.05% |
Observational | 22 (0.32%) | 0.25% |
Other | 4,747 (69.58%) | 84.16% |